Form 4: Harmony Biosciences CSO Reports Equity Transactions

Harmony Biosciences' Chief Strategy Officer, Andrew Serafin, reported the acquisition of new stock options and restricted stock units, alongside the vesting and tax-related disposition of previously granted equity.

Summary

• Andrew Serafin, Chief Strategy Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported several equity transactions.
• On January 22, 2026, Serafin was granted 42,600 stock options with an exercise price of $36.76, vesting 25% on January 22, 2027, and quarterly thereafter for four years.
• Also on January 22, 2026, Serafin was granted 12,200 Restricted Stock Units (RSUs), vesting in four equal annual installments beginning January 22, 2027.
• On January 24, 2026, 2,500 previously granted RSUs (from January 24, 2024 award) vested, resulting in the acquisition of 2,500 shares of Common Stock.
• Concurrently on January 24, 2026, 1,116 shares of Common Stock were disposed of at a price of $36.82 to satisfy income tax withholdings related to the RSU vesting.
• On January 25, 2026, 2,600 previously granted RSUs (from January 25, 2025 award) vested, resulting in the acquisition of 2,600 shares of Common Stock.
• Concurrently on January 25, 2026, 1,126 shares of Common Stock were disposed of at a price of $36.82 to satisfy income tax withholdings related to the RSU vesting.
• Following these transactions, Serafin beneficially owns 1,384 shares of Common Stock from the January 24, 2026 vesting and 1,474 shares from the January 25, 2026 vesting.
• Serafin also beneficially owns 42,600 stock options, 12,200 RSUs from the January 22, 2026 grant, 5,000 RSUs from the January 24, 2024 grant, and 7,800 RSUs from the January 25, 2025 grant.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there were dispositions of shares, these were for tax purposes related to vesting. The significant grants of new stock options and restricted stock units to a key executive indicate continued alignment of management's interests with long-term company performance and shareholder value, which is generally viewed favorably.

Positives

• Andrew Serafin received a significant grant of 42,600 stock options and 12,200 Restricted Stock Units, aligning his interests with long-term shareholder value.
• The vesting of previously granted RSUs demonstrates the ongoing execution of the company's equity compensation plan, rewarding executive performance.

Negatives

• A total of 2,242 shares of Common Stock were disposed of (1,116 shares on January 24, 2026, and 1,126 shares on January 25, 2026) to cover income tax withholdings, reducing direct beneficial ownership.

Future Outlook

The filing details future vesting schedules for stock options and restricted stock units, indicating continued equity compensation for the Chief Strategy Officer, contingent on his continued service. The stock options granted on January 22, 2026, will vest 25% on January 22, 2027, with the remainder vesting quarterly until January 22, 2030. The restricted stock units granted on January 22, 2026, will vest in four equal annual installments starting January 22, 2027.

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and insider holdings, demonstrating alignment of executive incentives with company performance through equity awards.
• Employees: Reflects the company's ongoing use of equity compensation as part of its executive remuneration strategy.

Next Steps

• Continued vesting of stock options and restricted stock units on their scheduled dates, contingent on Andrew Serafin's continued service.
• Potential future dispositions of shares for tax withholding upon subsequent vesting events.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including new equity grants and the vesting of previous awards with associated tax withholdings. Such transactions are expected and do not typically provide new fundamental information that would warrant a change in investment recommendation. A 'hold' recommendation is appropriate as the filing does not alter the underlying investment thesis for Harmony Biosciences.

Keywords

Harmony Biosciences, HRMY, Andrew Serafin, Chief Strategy Officer, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Vesting